AI-enabled medical devices with limited pre-market validation are more likely to be recalled after FDA clearance.
Key Details
- 1AI-enabled device recalls are more common among those lacking prospective human validation prior to FDA 510(k) clearance.
- 2Most AI medical devices are cleared without requiring prospective clinical testing.
- 3Study reviewed all U.S. recalls of AI-enabled devices between Nov. 15–30, 2024.
- 4Validation method (none, retrospective, or prospective) was a notable factor influencing recall likelihood.
- 5Recalls were categorized into errors such as diagnostic, measurement, and functional issues.
Why It Matters
These findings highlight the inadequacy of current FDA pathways to ensure AI device reliability and safety in clinical environments. For radiology professionals and developers, the results underscore the critical importance of robust validation before market approval.
Source
Health Imaging
Related News
•AuntMinnie
Multimodal LLMs Show Improved Performance on Japanese Radiology Board Exams
New multimodal large language models (LLMs) like OpenAI o3 and Gemini 2.5 Pro demonstrated significant advancements in answering Japanese radiology board exam questions, particularly with image input.
•Radiology Business
Medicare Denies Over Half of Radiology AI Claims, Study Finds
Medicare denied $16 million in radiology AI claims between 2018 and 2023, rejecting over half submitted.
•Health Imaging
AI Model Improves Short-Term Breast Cancer Risk Prediction
AI models combining mammography and clinical data improve identification of women at high short-term breast cancer risk.